Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...

Obesity is one of the greatest burdens of global public health. One major factor that drives obesity is excessive fat ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Scientists working at Harvard University have uncovered new evidence that molecules made by gut bacteria travel straight to ...

Since their introduction, GLP-1 medications have rapidly gained popularity for their effectiveness in helping people manage ...

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

Obesity is independently associated with an increased prevalence of tinnitus, according to a study published online Nov. 2 in ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...